RxDoctor Payments Data

Parin Desai, MD

Nephrology · Crystal Lake, ILNPI 1497913511

Payments from drug & device makers

$3,861in general payments, 2019–2025

Across 105 payments — averaging $36.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$1K
  • AstraZeneca$760
  • Amgen$357
  • Travere Therapeutics, Inc.$188
  • Bayer$183
  • Calliditas Therapeutics US Inc.$177
  • plus $858 from 15 others

What the payments were for

  • Consulting fees$1,21832%
  • Food & beverage$2,51465%
  • Education$1293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,861 in reported general payments places this provider in the 75th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$257,423
Medicare patients
387
Services billed
2,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$36,772
FarxigaDapagliflozin Propanediol43$36,758
EntrestoSacubitril/Valsartan14$20,976
LokelmaSodium Zirconium Cyclosilicate17$15,467
KerendiaFinerenone18$15,324
EliquisApixaban11$15,186
Potassium Chloride62$1,586
Tamsulosin Hcl41$1,339
Furosemide211$1,145
Amlodipine Besylate131$785
Bumetanide14$632
Potassium Citrate ErPotassium Citrate20$624
Calcitriol39$580
Midodrine Hcl14$504
Metoprolol Succinate24$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$760$52,22660 claims
Boehringer IngelheimJardiance$78$36,77231 claims
NovartisEntresto$91$20,97614 claims
BayerKerendia$183$15,32418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 524 nephrology providers in Illinois.

Other nephrology in Crystal Lake

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →